EX-99.1 2 d647338dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    NEWS RELEASE

Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update

Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) at Two Scientific Meetings

Published Data from Phase 1 Study of Marzeptacog Alfa (Activated) in the Journal of Thrombosis & Haemostasis

Ended Q3 with a cash balance of ~$129M

SOUTH SAN FRANCISCO, Calif. – November 1, 2018 – Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced operating and financial results for the third quarter ending September 30, 2018 and provided a corporate update.

Recent Milestones:

 

 

Reported positive interim data from its Phase 2/3 study of subcutaneous (SQ) prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA), being developed for the treatment of hemophilia A or B with inhibitors at the 2018 meeting of the International Society for Thrombosis & Hemostasis (ISTH) in Dublin, Ireland on July 18th and presented updated data in the Subcutaneous Delivery of Coagulation Factors session at the 2018 Hemophilia Drug Development Summit (HDDS) in Boston, MA on August 15th.

 

 

Published data from the Phase 1 trial of MarzAA in individuals with hemophilia A or B with or without inhibitors in the peer-reviewed Journal of Thrombosis & Haemostasis. The paper, entitled: “Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia,” described the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending intravenous (IV) bolus doses of MarzAA.

 

 

Initiated a comprehensive review of the Cohort 6 neutralizing antibody (nAb) observation from the Phase 1/2 study of Factor IX (FIX) variant dalcinonacog alfa (DalcA). We are planning to provide further updates on these analyses later in 2018.

“We had an active third quarter in which we presented interim data on our ongoing Phase 2/3 SQ study of MarzAA at the 2018 ISTH & HDDS meetings and published data from our Phase 1 IV trial of MarzAA in the Journal of Thrombosis & Haemostasis,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We are very encouraged by the interim data from the Phase 2/3 study of MarzAA and plan to complete enrollment of the Phase 2 portion by the end of 2018. Simultaneously, we initiated an analysis of the nAb results from the Phase 1/2 study of dalcinonacog alfa (DalcA)(formerly CB 2679d/ISU304) Factor IX program. Our Q3 ending cash balance of $129M allows us to continue the independent development of our subcutaneous prophylactic MarzAA and DalcA candidates.”


LOGO    NEWS RELEASE

 

Upcoming Milestones

 

 

Interim analysis from the Phase 2/3 MarzAA study at ASH 2018.

 

 

Additional data and analysis of the cause and impact of the antibody observations in Cohort 6 of the dalcinonacog alfa (DalcA) Phase 1/2 trial in December 2018.

Second Quarter 2018 Results and Financial Highlights

 

 

Cash, cash equivalents and short-term investments, as of September 30, 2018 were $129.2 million due primarily to the approximately $106.8 million in net financing in February 2018 and $9.5 million in proceeds from the exercise of warrants during the first quarter 2018.

 

 

Research and development expense for the three months ended September 30, 2018 was $5.6 million, compared with $3.8 million for the prior year period. The increase was due primarily to personnel-related costs, preclinical third-party research and development service contracts and manufacturing expenses for MarzAA and DalcA.

 

 

General and administrative expense for the three months ended September 30, 2018 was $2.8 million compared with $2.4 million for the prior year period. The increase was due primarily to personnel related expenses and professional service costs.

 

 

Interest and other income for the three months ended September 30, 2018 was $0.7 million, compared with $0.1 for the prior year period. The increase was due primarily to investment and dividend income.

 

 

Net loss attributable to common stockholders for the three months ended September 30, 2018 was $7.7 million, or ($0.64) per basic and diluted share, compared with $5.8 million, or ($1.34) per basic and diluted share, for the prior year period.

 

 

On February 19, 2018, the final $5 million of the company’s redeemable convertible notes matured and were repaid in full with $5 million from the company’s restricted cash. The Company has no outstanding notes or debt.

 

 

As of September 30, 2018, the Company had 11,942,729 shares of common stock outstanding.

About Catalyst Biosciences

Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.


LOGO    NEWS RELEASE

 

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about development plans for Catalyst’s MarzAA and DalcA, including the potential completion of the Phase 2 portion of the Phase 2/3 trial of MarzAA by the end of 2018, plans to present interim analysis from this trial at ASH 2018, plans to complete the ongoing analysis of nAbs for DalcA by December 2018, and the potential resumption of clinical trials of DalcA. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that the ongoing Phase 2/3 efficacy trial may not replicate the results from earlier studies, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of antibodies, that the analysis of the nAbs observed in the Phase 1/2 trial of DalcA or other factors lead us not to resume clinical trials of DalcA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018, along with other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contacts:

Investors:

Fletcher Payne, CFO

Catalyst Biosciences, Inc.

1.650.871.0761

investors@catbio.com

Media:

Josephine Belluardo, Ph.D.

LifeSci Public Relations

1.646.751.4361

jo@lifescipublicrelations.com


LOGO    NEWS RELEASE

 

Catalyst Biosciences, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

 

     September 30,
2018
    December 31,
2017
 
     (Unaudited)        

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 35,998     $ 14,472  

Short-term investments

     93,223       17,971  

Restricted cash

     50       5,333  

Prepaid and other current assets

     3,538       1,333  
  

 

 

   

 

 

 

Total current assets

     132,809       39,109  

Other assets, noncurrent

     352       128  

Property and equipment, net

     255       276  
  

 

 

   

 

 

 

Total assets

   $ 133,416     $ 39,513  
  

 

 

   

 

 

 

Liabilities and stockholders’ equity

    

Current liabilities:

    

Accounts payable

   $ 369     $ 747  

Accrued compensation

     1,082       1,366  

Other accrued liabilities

     1,840       1,322  

Deferred revenue

     —         212  

Deferred rent, current portion

     13       7  

Redeemable convertible notes

     —         5,085  
  

 

 

   

 

 

 

Total current liabilities

     3,304       8,739  

Deferred rent, noncurrent portion

     161       —    
  

 

 

   

 

 

 

Total liabilities

     3,465       8,739  
  

 

 

   

 

 

 

Stockholders’ equity:

    

Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 and 3,680 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively

     —         —    

Common stock, $0.001 par value, 100,000,000 shares authorized; 11,942,729 and 6,081,230 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively

     12       6  

Additional paid-in capital

     322,468       204,262  

Accumulated other comprehensive income

     (24     —    

Accumulated deficit

     (192,505     (173,494
  

 

 

   

 

 

 

Total stockholders’ equity

     129,951       30,774  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 133,416     $ 39,513  
  

 

 

   

 

 

 


LOGO    NEWS RELEASE

 

Catalyst Biosciences, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2018     2017     2018     2017  

Contract revenue

   $ —       $ 318     $ 6     $ 700  

Operating expenses:

        

Research and development

     5,575       3,805       13,235       9,286  

General and administrative

     2,770       2,391       8,909       7,407  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     8,345       6,196       22,144       16,693  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (8,345     (5,878     (22,138     (15,993

Interest and other income, net

     651       85       2,920       185  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (7,694   $ (5,793     (19,218     (15,808
  

 

 

   

 

 

   

 

 

   

 

 

 

Deemed dividend for convertible preferred stock beneficial conversion feature

     —         —         —         (3,951
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to common stockholders

   $ (7,694   $ (5,793   $ (19,218   $ (19,759
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (0.64   $ (1.34   $ (1.75   $ (6.49
  

 

 

   

 

 

   

 

 

   

 

 

 

Shares used to compute net loss per share attributable to common stockholders, basic and diluted

     11,942,729       4,310,561       10,967,750       3,043,919